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Table
Demographics
N 88
Age in years (range) 6  5.8* (0.67-18)
Male 63%
Donor Source
Bone Marrow 44
Peripheral Stem Cells 43
Umbilical Cord Blood 1
Stem Cell Dose (CD34 x106/kg
body weight)
7.94  6.45* (0.85-33)
Type of Transplantation
Autologous 32
Allogeneic 56
GVHD Prophylaxis
Cyclosporine and Methotrexate 32
Tacrolimus and Methotrexate 9
Other 11
OUTCOMES
PO ACV in mg/kg/dose (range) 9.8  3.5* (2.4-28)
PO ACV in mg/dose (range) 200  105* (100-400)
Duration of PO ACV in days (range) 345  154*(7-1337)
Number of VZV Reactivations 1
Time from Transplantation to VZV
Reactivation (range)
498 days
Deaths 3 (relapsed)
1 (cardiac arrest)
Deaths due to VZV 0
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in HSCT patients deemed high-risk for IFI; this has led to
long-term use of voriconazole following allogeneic HSCT in
patients that remain immunocompromised. Voriconazole
has three ﬂuoride atoms and has been associated with
periostitis, exostoses, and ﬂuoride toxicity in patients taking
voriconazole following solid organ transplant, HSCT and
leukemia therapy.
Objectives: To describe the incidence of ﬂuoride toxicity in
allogeneic HSCT patients taking voriconazole that had
a ﬂuoride level measured, identify when a ﬂuoride level was
measured due to symptomatic ﬂuoride toxicity in relation to
voriconazole initiation, and describe the clinical presentation
and outcomes of patients with ﬂuoride toxicity in HSCT
patients.
Methods: Retrospective review of all adult allogeneic HSCT
patients at Mayo Clinic Rochester between 1/1/09 e 7/31/12.
Fluoride assays were conducted with an ion selective elec-
trode (normal range 0 e 4 mmol/L).
Results: 292 patients received an allogeneic HSCT between
1/1/09 e 7/31/12. Patients were excluded if they did not
consent to research (n¼4), were treated by the pediatric
service (n¼7), or did not receive voriconazole formore than 7
days (n¼38). The median duration of voriconazole was 167
days (range 7e1321). Of 243 patients included, 32 presented
with musculoskeletal pain and had a ﬂuoride assay. In 31
patients with ﬂuoride measured while on voriconazole, 29
(93.5%) had elevated ﬂuoride levels; 1 patient had a normal
ﬂuoride level measured 1 month after voriconazole discon-
tinuation due to pain. The median ﬂuoride level was 10.5
mmol/L (range 2-24.7). The median time to measurement of
ﬂuoride was 113 days following voriconazole initiation
(range 28e 692). Of the 29 patients with an elevated ﬂuoride
level, pain improved in 17 patients following voriconazole
discontinuation; 2 patients did not have improvement after
holding voriconazole for 1 week and resumed voriconazole.
Four patients had repeat ﬂuoride measurement and subse-
quently discontinued voriconazole because of pain; pain
improved in 2 of those patients, did not improve in 1 patient
and 1 patient was not assessed. Six patients continued vor-
iconazole; pain resolved in 4 of those patients, was not
assessed in 1 patient and persisted in 1 patient with recur-
rent leukemia. Eight patients (27.6%) with elevated ﬂuoride
levels had an estimated glomerular ﬁltration rate < 50 mL/
min.
Conclusions: Of 243 consecutive allogeneic HSCT patients
receiving voriconazole for more than 7 days, the devel-
opment of musculoskeletal pain in 32 (13.2%) patients led
to ﬂuoride assessment; 29 patients (93.5%) with ﬂuoride
levels measured while on voriconazole had elevated
levels. Fluoride toxicity is an adverse effect of vor-
iconazole that should be considered in patients present-
ing with pain and is often reversible following drug
discontinuation.549
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Oncology/BMT, Nationwide Children's Hospital, Columbus, OHBackground: Prophylaxis with low-dose acyclovir is effec-
tive in lowering the incidence of Varicella zoster virus (VZV)
reactivation and infections during the ﬁrst year post-trans-
plant in adult hematopoietic stem cell transplantation
(HSCT) patients. Such data are lacking in the pediatric pop-
ulation. The objective of this study was to determine the
effectiveness of low-dose acyclovir prophylaxis in preventing
VZV reactivations and infections in the pediatric HSCT
patients.
Methods Medical records of VZV seropositive patients,
< 18 years of age who received a HSCT between January
2000 and April 2010 were retrospectively reviewed for:
demographics, pre-transplant serology for herpes simplex
virus, VZV and cytomegalovirus, acyclovir (ACV) dosing
both intravenous (IV) and oral (PO), duration of acyclovir
prophylaxis, incidence of reactivation, time to reac-
tivation, age at reactivation, acyclovir prophylaxis status at
the time of reactivation, severity of zoster infection,
duration of follow-up, graft versus host disease (GVHD)
prophylaxis, incidence of GVHD, treatment of acute or
chronic GVHD, deaths, cause of death, and any adverse
effects attributed to acyclovir. Data was analyzed using
descriptive statistics.
Results:Conclusion: ACV at a median dose of 20 mg/kg/day twice
daily was successful in preventing reactivations of VZV in 99
% of pediatric HSCT patients. The median duration of oral
ACV prophylaxis in these patients was 345 days. Reac-
tivation was detected by a qualitative polymerase chain
reaction test positive for the viral DNA in a superﬁcial tissue
sample. Repeat test conducted three weeks later was
negative. The patient was not on ACV at the time of reac-
tivation, did not require treatment for VZV infection, but
was started on valacylovir prophylaxis. According to the
guidelines for preventing infectious complications among
HSCT recipients, the recommended oral ACV dose for VZV
prophylaxis is 60-80 mg/kg/day in two to three divided
doses for children <40 kg body weight and 800 mg of oral
ACV twice daily for children >40 kg body weight. At a dose
All patients Mean AUC24h
21 days (ng.h/mL)
Mean C0 21 days
(ng/mL)
12 581 Minimum
6531
Maximum
20168
202 Minimum
78
Maximum
430
With GVHD 12 561 p ¼ 0.98 193 p ¼ 0.64
No GVHD 12 590 205
With
nephrotoxicity
12 345 p ¼ 0.611 214 p ¼ 0.360
No
nephrotoxicity
12 765 193
Abstracts / Biol Blood Marrow Transplant 19 (2013) S370eS380 S379lower than recommended, the incidence of VZV reactivation
was low.
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Background: Multiple myeloma (MM) is the most
common plasma cell disorder with an incidence of 4-5
new cases per 100,000 individuals per year. High dose
chemotherapy with melphalan followed by autologous
stem cell transplantation (SCT) is considered the standard
of care. Melphalan 200 mg/m2 is considered the gold
standard conditioning regimen prior to autologous SCT.
The Intergroupe Francophone du Myélome randomized
trial conﬁrmed that patients receiving melphalan 200 mg/
m2 displayed a better median overall survival as
compared to patients treated with melphalan 140 mg/m2
in combination with total body irradiation (65 vs. 45%
survival at 45 months). Melphalan 200 mg/m2 has been
administered over 1-day or given over two consecutive
days (100 mg/m2 per day). Limited data exist on optimal
schedule of dosing and to date, direct comparative
efﬁcacy analyses have not been conducted between 1-day
versus 2-day melphalan administration. As of March
2012, the Blood and Marrow Transplantation Service at
Mofﬁtt Cancer Center changed the melphalan condi-
tioning regimens from 2-day dosing (100 mg/m2 per day)
to 1-day dosing (200 mg/m2per day). An evaluation
will be performed in order to determine if there is
a difference in the effects on patients’ transplant
complications, engraftment, and response rates between
the two groups.
The dose-limiting toxicity of melphalan is oral muco-
sitis which is associated with prolonged hospitalization.
Grazziutti, et al found that higher melphalan doses and
renal dysfunction (both reﬂecting increased melphalan
exposure) were key pre-transplant risk factors for severe
oral mucositis following autologous SCT; all doses were
administered over 1-day. Parallel to this study, Palumbo, et
al found a greater incidence of non-hematologic toxicities
in patients who received higher doses of melphalan
although this study evaluated melphalan 200 mg/m2
versus 100 mg/m2; all doses were administered over 1-day.
Along with toxicity proﬁle, it is unknown whether
administering melphalan over 1-day versus 2-days will
affect response rates post-transplantation and progres-
sion-free survival of patients. We propose a retrospective
comparison between patients who have received 1-day
melphalan versus 2-day melphalan to evaluate these
outcomes.
Study Design: A retrospective chart review of all patients
with MM receiving high dose melphalan for autologous SCT
from January 2010-October 2012 will be conducted.
Patient Population: Inclusion criteria:1 All patients with primary diagnosis of MM undergoing
autologous SCT
2 Conditioning regimen consisting of melphalan 200
mg/m2
3 18 years of age and older
Exclusion criteria:
1 Patients who received reduced dose melphalan, 140
mg/m2, as conditioning regimen
2 For patients who received tandem autologous SCT, only
the ﬁrst SCT will be evaluated
Results: Preliminary results to be presented.551
Therapeutic Drug Monitoring (TDM) of Cyclosporine
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Introduction: The controversy surrounding cyclosporine
TDM is still ongoing. In HSCT practice, the C0 method (or
trough) is the one most commonly employed. At the CHU
Sainte-Justine, the AUC method has been used for cyclo-
sporine TDM in HSCT patients since October 2009. The aim of
this study was to evaluate the correlation between cyclo-
sporine levels (AUC or C0) with nephrotoxicity and GVHD in
a pediatric population.
Methods: Forty-seven patients treated by IV cyclosporine for
a ﬁrst HSCT and having at least two AUCs were included in
this retrospective study. Our protocol stipulates that
a complete AUC (9 samples) must be done seven days after
the beginning of the intravenous cyclosporine and partial
AUCs (3 samples) once a week. All AUCs also include a C0.
GVHDwas deﬁned as acute or chronic GVHD of any grade for
the duration of the post-transplant follow-up. The patients
were evaluated for the occurrence of nephrotoxicity
according to the AKIN criteria.
Results: Median age of patients was 10.4 years (0.19-20.9).
A total of 176 AUC samples were included (55 complete
and 121 partial). Fourteen patients (30%) were diagnosed
with GVHD and 23 (49%) with nephrotoxicity (AKIN stage
1, 2 or 3 at least one day for the duration of the IV
cyclosporine).Conclusion: No correlation was found between the cyclo-
sporine levels (AUC or C0) and the occurrence of GVHD or
nephrotoxicity. Many confounding factors can inﬂuence
theses issues and the small number of patients limits the
extent of these ﬁndings.
